Research programme: mRNA based cancer vaccines - CureVac/myNEO
Latest Information Update: 17 Oct 2024
Price :
$50 *
At a glance
- Originator CureVac; myNEO
- Class Antineoplastics; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Sep 2024 Pharmacodynamics data from preclinical studies in Cancer presented at CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference (CICON-2024)
- 29 Feb 2024 Preclinical trials in Cancer in USA (unspecified route), before February 2024
- 25 May 2022 myNEO and CureVac agree to develop mRNA based cancer vaccines